M1

Fidelis Cybersecurity Strengthens Ransomware Capabilities

Retrieved on: 
Tuesday, April 5, 2022

Fidelis Cybersecurity today announced Fidelis Endpoint, a favored solution of forensics and incident response professionals worldwide, successfully detected Data Encrypted For Impact (T1486) , which is indicative of Ransomware attacks, during the 2021 MITRE Engenuity Round 4 ATT&CK Evaluation.

Key Points: 
  • Fidelis Cybersecurity today announced Fidelis Endpoint, a favored solution of forensics and incident response professionals worldwide, successfully detected Data Encrypted For Impact (T1486) , which is indicative of Ransomware attacks, during the 2021 MITRE Engenuity Round 4 ATT&CK Evaluation.
  • Fidelis Cybersecurity also announced new and enhanced features, including advanced memory scanning, that will improve customers ability to quickly find and neutralize Ransomware and other malware.
  • Fidelis Endpoint is available as a standalone offering or as part of Fidelis Elevate, an Active eXtended Detection and Response (XDR) platform.
  • Fidelis Cybersecurity, the industry innovator in Active XDR and proactive cyber defense solutions, safeguards modern IT environments with unparalleled detection, deception, response, cloud security, and compliance capabilities.

BlueSky Statistics' Comprehensive R GUI Gets Major Overhaul, Mac Version, Reproducibility, and more

Retrieved on: 
Tuesday, April 5, 2022

CHICAGO, April 5, 2022 /PRNewswire-PRWeb/ -- BlueSky Statistics just announced a major new version (10.0) of their comprehensive R GUI for statistics and data science. "BlueSky Statistics 10 puts even more of R's power into everyone's hands," said Sanjay Kumar, CEO, and Founder of BlueSky Statistics. "It has both the efficiency of a no-code GUI with full reproducibility for all users and an R code editor for programmers".

Key Points: 
  • "BlueSky Statistics 10 puts even more of R's power into everyone's hands," said Sanjay Kumar, CEO, and Founder of BlueSky Statistics.
  • "It has both the efficiency of a no-code GUI with full reproducibility for all users and an R code editor for programmers".
  • BlueSky Statistics provides a GUI (Graphical user interface) with hundreds of popular data preparation, graphics, statistics, machine learning, and model fitting methods.
  • In addition, BlueSky Statistics delivers a powerful framework for extensibility to build GUIs for any R function in minutes.

M1 MedTech Accelerator Program Opens Applications to Early-Stage Medical Device Companies

Retrieved on: 
Monday, April 4, 2022

M1 MedTech is looking for five to seven of the most promising early-stage medical device companies to participate in its three-month program.

Key Points: 
  • M1 MedTech is looking for five to seven of the most promising early-stage medical device companies to participate in its three-month program.
  • Access to the M1 founders network, both within and outside of the Texas Medical Center, sets these companies up for success.
  • M1 MedTech was created to support early-stage medical device companies, offering an immersive experience that provides tangible benefits to participating companies.
  • This is a very personalized program for early-stage companies focused on Class II and III medical devices, said Sean Bittner , PhD, ACC, Director of Programs at M1 MedTech.

DGAP-News: M1 Kliniken AG publishes preliminary figures for financial year 2021: revenue rises to € 315 million; pre-tax profit amounts to € 14.4 million

Retrieved on: 
Friday, April 1, 2022

M1 Kliniken AG publishes preliminary figures for financial year 2021: revenue rises to 315 million; pre-tax profit amounts to 14.4 million

Key Points: 
  • M1 Kliniken AG publishes preliminary figures for financial year 2021: revenue rises to 315 million; pre-tax profit amounts to 14.4 million
    The issuer is solely responsible for the content of this announcement.
  • M1 Kliniken AG publishes preliminary figures for financial year 2021: revenue rises to 315 million; pre-tax profit amounts to 14.4 million
    Berlin, 30.03.2022 - M1 Kliniken AG (ISIN: DE000A0STSQ8) publishes preliminary figures for the 2021 financial year.
  • In the 2021 financial year, the M1 Group was able to increase consolidated group sales by almost 100% to 314.6 million (previous year: 159.6 million).
  • The operating profit 2021 (EBIT) of the M1 Group amounted to 12.1 million euros and thus almost tripled the previous year's value (previous year 4.4 million euros).

Issuances in Prospect Capital Corporation Preferred Stock Offerings Total Approximately $600 Million Across Institutional, Registered Investment Advisor, Wirehouse, Independent Private Wealth, and International Investors 

Retrieved on: 
Monday, March 28, 2022

"Each of the institutional, registered investment advisors, wirehouse, independent private wealth, and international investor channels have invested in Prospects preferred stock."

Key Points: 
  • "Each of the institutional, registered investment advisors, wirehouse, independent private wealth, and international investor channels have invested in Prospects preferred stock."
  • Preferred Capital Securities LLC (PCS) is a securities broker dealer and the dealer manager for the ongoing offering of the Series A1, M1, and M2Preferred Stock.
  • Prospect Capital Corporation is a business development company that focuses on lending to and investing in private businesses.
  • Prospect has elected to be treated as a business development company under the Investment Company Act of 1940 (1940 Act).

Quanergy Industrial LiDARs Selected by Vecna Robotics to Democratize Autonomous Co-bots for Material Handling

Retrieved on: 
Monday, March 28, 2022

(NYSE: QNGY), a leading provider of LiDAR sensors and smart 3D solutions, today announced its M1 LiDAR sensors have been chosen by Vecna Robotics to deliver natural feature navigation for their new Vecna CPJ autonomous co-bot pallet jack.

Key Points: 
  • (NYSE: QNGY), a leading provider of LiDAR sensors and smart 3D solutions, today announced its M1 LiDAR sensors have been chosen by Vecna Robotics to deliver natural feature navigation for their new Vecna CPJ autonomous co-bot pallet jack.
  • View the full release here: https://www.businesswire.com/news/home/20220328005137/en/
    Quanergy Industrial LiDARs Selected by Vecna Robotics to Democratize Autonomous Co-bots for Material Handling (Graphic: Business Wire)
    Quanergys M1 LiDAR sensors are key to achieving our objective of democratizing the adoption of robots in the material handling space, said Zachary Dydek, Chief Technology Officer at Vecna Robotics.
  • Vecna CPJ leverages Quanergys M1 LiDAR sensors for natural feature navigation to help bring automation to long-ignored material handling workflows like pallet and tote consolidation, pick-to-packout, and QA/QC/rework.
  • Vecna Robotics is an award-winning flexible, intelligent material handling automation company with solutions engineered for seamless work between autonomous mobile robots (AMR) and the labor, equipment, facilities, and systems that make business go.

Pipeline Therapeutics Receives IND Clearance from FDA to Initiate Phase 1b/2a Study of PIPE-307 in Patients with Relapsing-Remitting Multiple Sclerosis

Retrieved on: 
Monday, March 28, 2022

FDA clearance to initiate our Phase 1b/2a clinical study of PIPE-307 is a major regulatory milestone for Pipeline, as it allows us to proceed with the evaluation of PIPE-307 in RRMS patients, said Carmine Stengone, President and CEO of Pipeline.

Key Points: 
  • FDA clearance to initiate our Phase 1b/2a clinical study of PIPE-307 is a major regulatory milestone for Pipeline, as it allows us to proceed with the evaluation of PIPE-307 in RRMS patients, said Carmine Stengone, President and CEO of Pipeline.
  • Our objective with PIPE-307 is to develop the first effective treatment that can restore myelin and improve outcomes for patients.
  • The Phase 1b/2a clinical trial of PIPE-307 will be conducted as a randomized, double-blind, placebo-controlled dose-ranging study in multiple sites across the US.
  • In March 2022, the Company received clearance from the U.S. Food and Drug Administration to proceed with a Phase 1b/2a study of PIPE-307 in RRMS patients.

Kairos Pharma Receives FDA Approval of Investigational New Drug (IND) Application for Its Phase 1 Clinical Trial of KROS 201 for the Treatment of Glioblastoma; Announces New Patent for KROS 401

Retrieved on: 
Monday, March 14, 2022

LOS ANGELES, March 14, 2022 /PRNewswire/ -- Kairos Pharma, Ltd. ("Kairos"), a privately held clinical stage biotechnology company focused on drug resistance and immunotherapy for cancer, today announced that its activated T cell therapy, KROS 201, has received FDA approval to proceed with a Phase 1 clinical trial in patients with recurrent glioblastoma, a type of brain cancer.  The phase I trial is sponsored by Kairos Pharma and will be conducted at Cedars Sinai Medical Center in Los Angeles. 

Key Points: 
  • The phase I trial is sponsored by Kairos Pharma and will be conducted at Cedars Sinai Medical Center in Los Angeles.
  • commented, "This IND acceptance is the second substantial clinical milestone within the past month as Kairos accelerates toward its clinical goals for 2022.
  • This first-in-man Phase 1 clinical trial will activate T cells against the cancer stem cells at the root of glioblastoma."
  • Kairos Chief Scientific Officer Neil Bhowmick, Ph.D. added, "This achievement pushes the envelope of immune therapies designed to target T cells against devastating cancers."

UScellular to Offer All-New iPhone SE and iPad Air with 5G on March 18

Retrieved on: 
Friday, March 11, 2022

CHICAGO , March 11, 2022 /PRNewswire/ -- UScellular will offer the powerful iPhone SE with exceptional capabilities and performance at an incredible price, sophisticated alpine green iPhone 13 Pro and stunning green iPhone 13, and the powerful and versatile iPad Air with the breakthrough M1 chip.

Key Points: 
  • Customers can also order iPhone 13 and Pro iPhone 13 Pro Max in alpine green, and iPhone 13 and iPhone 13 mini in green, in addition to the iPad Air, on March 11, with availability on March 18.
  • "We're also sure our customers will love the new alpine green iPhone 13 Pro and green iPhone 13 in the iPhone lineup, and the new iPad Air with 5G and Apple's M1 chip is an impressive mix of power and efficiency."
  • The new green iPhone 13 and iPhone 13 mini completes the lineup which includes (PRODUCT)RED, starlight, midnight, blue, and pink.
  • The new iPhone SE, iPhone 13 Pro in alpine green and iPhone 13 in green are now available to pre-order at UScellular.

Issuances in Prospect Capital Corporation Preferred Stock Offerings Exceed $550 Million Across Institutional, Registered Investment Advisor, Wirehouse, Independent Private Wealth, and International Investors

Retrieved on: 
Friday, March 11, 2022

"Each of the institutional, registered investment advisor, wirehouse, independent private wealth, and international investor channels have invested in Prospects preferred stock."

Key Points: 
  • "Each of the institutional, registered investment advisor, wirehouse, independent private wealth, and international investor channels have invested in Prospects preferred stock."
  • Preferred Capital Securities LLC (PCS) is a securities broker dealer and the dealer manager for the ongoing offering of the Series A1, M1, and M2Preferred Stock.
  • Prospect Capital Corporation is a business development company that focuses on lending to and investing in private businesses.
  • Prospect has elected to be treated as a business development company under the Investment Company Act of 1940 (1940 Act).